Search
Flickr PhotoStream
Archive for the ‘Drugs’ Category
The second day of the conference continued with more government perspectives on the effect of the MMA. FDA Commissioner Mark McClellan, newly nominated by President George W. Bush to head the CMS, stated that many senior citizens are considering gambling on the safety and effectiveness of their medications (i.e., buying re-imported medications) because they have [...]
- In: Drugs
- Tags: Drug Congress, Drug Manufacturers, FDA Perspective
Thomas Scully, former CMS administrator, gave several examples “from the battlefield” of the prescription drug legislation and its potential impact on American senior citizens and health care in general. He touted the MMA as “the deal of the century and millennium” and as a “spectacular deal for rich and poor seniors.”
- In: Drugs
- Tags: Drug Congress, Drug Manufacturers, FDA Perspective
The National Medicare Prescription Drug Congress
21, May 2010With a deadline of June 1, 2004, looming for the beginning of the Medicare Prescription Drug Plan (PDP) Discount Card program, a consortium of more than 30 organizations co-sponsored the National Medicare Prescription Drug Congress on Capitol Hill in Washington, DC, from February 25-27, 2004. The main objective was to assess the various areas of [...]
- In: Drugs
- Tags: Drug Congress, Drug Manufacturers, FDA Perspective
Suggestions for Resolving Conflicts in Drug Therapy
16, May 2010PROBLEM: Many serious medication errors that have been reported to the Institute for Safe Medication Practices (ISMP) have involved drug orders that were considered by at least one practitioner to be unsafe. In some cases, the practitioners did not question the orders, because they were reluctant to challenge the prescriber. More often, the practitioners questioned [...]
- In: Drugs
- Tags: Drug Therapy
Second-Generation Antipsychotic Agents
15, May 2010By now, most readers know that I am not a psychiatrist! I was intrigued to read about a recent consensus development conference on the use of antipsychotic drugs and the development of obesity and diabetes—frankly, a connection that I had not realized.
- In: Drugs
- Tags: Antipsychotic Agents
Subsequent Prescribing of New Drugs: DISCUSSION
9, May 2010Clinical investigators are integral to the drug-development process. They often play an important additional role in the adoption of new drugs, particularly for first-in-class agents. In the U.S., most investigators are practicing physicians in office or hospital settings, with only a portion of them based in medical schools and teaching hospitals. These practicing investigators, although not [...]
- In: Drugs
- Tags: New Drugs, Subsequent Prescribing
Subsequent Prescribing of New Drugs: RESULTS
8, May 2010In the three months prior to the drug’s launch, both investigator and control physicians wrote a mean of 2.2% of all their prescriptions from the pharmaceutical company launching the new drug (SD ± 6.0 for the investigators, SD 4.3 for the control physicians). During this time, investigators wrote a mean total of 677 prescriptions (SD [...]
- In: Drugs
- Tags: New Drugs, Subsequent Prescribing